# Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
Canonical URL: https://biopharmsignal.com/news/MDNA/medicenna-presents-positive-data-demonstrating-superior-safety-and-efficacy-potential-of-its-first-in-class-anti-pd-1-x-il-2-bifunctional-superkine-mdna113-at-aacr-2026
Ticker: MDNA
Company: Medicenna Therapeutics Corp.
Source: Medicenna Therapeutics Corp.
Published: 2026-04-21 11:30 EST
Original Source URL: https://ir.medicenna.com
## Summary

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head non-human primate comparison against an anti-PD-1 x IL-2α-biased bispecific demonstrates MDNA113’s

## Article Body
New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head non-human primate comparison against an anti-PD-1 x IL-2α-biased bispecific demonstrates MDNA113’s
## Recent Company News
- 2026-06-03 11:00 EST — [Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026](https://biopharmsignal.com/news/MDNA/medicenna-s-mdna11-potential-in-earlier-line-melanoma-setting-highlighted-in-presentation-of-the-neo-cyt-trial-at-asco-2026) — Source: Medicenna Therapeutics Corp.
- 2026-05-28 13:10 EST — [Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs](https://biopharmsignal.com/news/MDNA/medicenna-announces-closing-of-public-offering-of-units-raising-cdn-4-44-million-to-support-lead-programs) — Source: Medicenna Therapeutics Corp.
- 2026-05-22 11:00 EST — [Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet](https://biopharmsignal.com/news/MDNA/medicenna-announces-the-filing-of-its-prospectus-supplement-and-investment-term-sheet) — Source: Medicenna Therapeutics Corp.
- 2026-05-19 11:00 EST — [Medicenna Announces the Finalization of the Terms of its Public Offering of Securities](https://biopharmsignal.com/news/MDNA/medicenna-announces-the-finalization-of-the-terms-of-its-public-offering-of-securities) — Source: Medicenna Therapeutics Corp.
- 2026-05-13 20:01 EST — [Medicenna Announces the Launch of a Marketed Public Offering of Securities](https://biopharmsignal.com/news/MDNA/medicenna-announces-the-launch-of-a-marketed-public-offering-of-securities) — Source: Medicenna Therapeutics Corp.
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)